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ORIGINAL ARTICLE
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Abstract
Systemic amyloidoses are a group of debilitating and often fatal diseases in which fibrillar
protein aggregates are deposited in the extracellular spaces of a range of tissues. The molecular
basis of amyloid formation and tissue localization is still unclear. Although it is likely that the
extracellular matrix (ECM) plays an important role in amyloid deposition, this interaction is
largely unexplored, mostly because current analytical approaches may alter the delicate and
complicated three-dimensional architecture of both ECM and amyloid. We describe here a
decellularization procedure for the amyloidotic mouse liver which allows high-resolution
visualization of the interactions between amyloid and the constitutive fibers of the extracellular
matrix. The primary structure of the fibrillar proteins remains intact and the amyloid fibrils
retain their amyloid enhancing factor activity.
Abbreviations: AA, amyloid A protein; (AA-mL), crude homogenates from non-decellularized
AA amyloidotic mouse liver; AA-mLdec, crude homogenates from decellularized AA amyloidotic
mouse liver; AEF, amyloid enhancing factor; ECM, extracellular matrix; H&E, hematoxylin and
eosin; IDA, industrial denatured alcohol; IVC, inferior vena cava; PV, portal vein; SAA, serum
amyloid A protein; SAP, serum amyloid P component; SDC, sodium deoxycholate; SEM,
scanning electron microscopy; SR, picro-Sirius red.
Keywords
AA amyloidosis, AEF, amyloid,
decellularized liver, scaffold
History
Received 21 August 2015
Revised 6 October 2015
Accepted 15 October 2015
Published online 8 December 2015
Introduction
Amyloidosis is a group of protein misfolding disorders in
which normal circulating proteins misfold and self-aggregate
into fibrillar polymers that precipitate in the extracellular
space [1]. The disease can be systemic when several organs
and connective tissue matrix are widely involved, or localized
if only a single anatomical site or organ system is affected. In
many cases of systemic amyloidosis, amyloid deposition is
most prominent in specific organs, such as the liver, the heart,
the spleen or the nerves, and this dictates the specific clinical
features. Although there is clinical and experimental evidence
suggesting that some specific constituents of the extracellular
matrix (ECM), such as proteoglycans may play a crucial role
in determining the specificity of tissue localization of amyloid
deposits [2], accurate analysis of the interaction between
amyloid and the biochemical and biophysical structure of the
ECM has been so far been limited by technical factors.
We speculated that the intimate relationship between ECM
and amyloid could be more precisely characterized in
amyloidotic tissue after cell removal. Decellularization of a
biopsy of amyloidotic tissue was first carried out in a
pioneering study by Bonsib and Plattner [3] in the attempt to
improve the microscopic visualization of amyloid, however
the decellularization of an entire amyloidotic organ has not
previously been undertaken. Notably, successful creation of
scaffolds for tissue regeneration has lately been achieved by
decellularization of whole organs [4–7]. The architecture of
the decellularized organ is maintained with the preservation
of the fine 3D structure of the ECM and of the vascular,
lymphatic and nervous networks [8]. Cells can be removed by
mild procedures which preserve not only the 3D architecture
but also the biochemical composition, the bioactivity and the
physical properties of the ECM [9]. We have previously
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shown that a specific detergent-enzymatic treatment [10]
preserves scaffold microarchitecture and microvascular net-
works allowing successful clinical transplantation of human
tracheas [11].
Here, we report in mice with transgenic overexpression of
mouse amyloid A (AA) [12] that hepatic AA amyloid deposits
[12] persisted in the ECM after complete decellularization of
the liver. The primary structure of the amyloid fibril protein
was unaffected by the procedure and amyloid extracted from
decellularized liver retained the amyloid enhancing factor
(AEF) property that accelerates, in vivo, AA amyloid
formation. In addition, scanning electron microscope (SEM)
images of the scaffold of the decellularized amyloidotic organ
provided a unique 3D visualization of the intimate relation-
ship between the amyloid fibrils and the ECM network.
Methods
Transgenic mice
Amyloidosis was induced in transgenic mice, which express
the amyloidogenic SAA1 isotype [13] (originally called
SAA2 [14]) when treated with doxycycline, as previously
described [12]. Briefly, AEF was injected into animals
receiving 2 mg/ml doxycycline in their drinking water for
10 days after AEF administration. This protocol consistently
results in extremely large amyloid loads [12].
Harvest of organs for decellularization
Mice were killed by CO2 inhalation. The abdomen was
cleaned with 70% ethanol and a U-shaped incision was
performed to expose the abdominopelvic cavity. The abdom-
inal inferior vena cava (IVC) and portal vein (PV) were
identified and the PV was cannulated with a 24G cannula
(Becton Dickinson, Franklin Lakes, NJ), which was secured
in place with a 3-0 silk suture (Ethicon, Somerville, NJ). The
abdominal IVC was sectioned and 200 U of heparin injected
into the portal vein. The diaphragm was used as a holding
point to release the whole liver from the supporting tissue.
The whole procedure was carried out with special caution not
to damage Glisson’s capsule, which surrounds the organ.
Decellularization
Mouse livers were connected to a peristaltic pump via the
cannulated PV and perfused with deionized water for 36 h at
4 C. Livers were then transferred to room temperature and
were perfused with 4% (w/v) sodium deoxycholate (SDC)
(Sigma, St Louis, MO) for 6 h followed by perfusion of
500 kU/ml of DNase-I from bovine pancreas (Sigma, St
Louis, MO) in 1 M sodium chloride (NaCl) for 3 h. The flow
rate was kept at 4.5 ml/min for the water infusion and 6.5 ml/
min for SDC and DNase steps. Following the end of the
decellularization cycle, the livers were perfused with PBS
with 1% antibiotic/antimycotic (Sigma, St Louis, MO) for
30 min and stored in the same buffer at 4 C.
Histology and immunohistochemistry
Samples were fixed for at least 24 h in 10% neutral buffered
formalin solution (pH 7.4) at room temperature. Tissue was
embedded in wax and sectioned at 4 mm. Sections were
dewaxed in xylene and rehydrated using graded industrial
denatured alcohol (IDA) before staining with Harris’s hema-
toxylin and eosin (H&E) (Leica Microsystems, Wetzlar,
Germany), or Picro-Sirius Red (SR) (VWR International,
Radnor, PA) or Miller’s Elastic with a SR counter stain (VWR
International, Radnor, PA; Leica Microsystems, Wetzlar,
Germany; Thermo Scientific, Waltham, MA).
For AA immunohistochemistry, 2 mm sections were de-
waxed, rehydrated and endogenous peroxidase blocked
with 0.6 % hydrogen peroxidase. Sections were then
washed in PBS, and non-specific antibody binding was
blocked by incubation in 2.5% v/v heat inactivated normal
horse serum (Vector Labs, Burlingame, CA) for 30 min at
room temperature. After washing, slides were incubated
with anti-mouse SAA antibody Ab AF2948 (R&D
Systems, Abingdon, UK) diluted in Dako Antibody
Diluent (1/100) overnight at 4 C. Slides were then
incubated with IMMpress anti-goat polymer (Vector
Labs, Burlingame, CA) for 30 min at room temperature,
washed and incubated for 10 min with DAB/Metal
(Thermo Scientific, Waltham, MA) diluted (1:10) in
stable H2O2 substrate buffer. After terminating the reaction
by washing, slides were counterstained with Myers hema-
toxylin for 30 s. Congo red staining was performed by the
method of Puchtler et al. [15]. Cross-polarized light
microscopy was used to reveal the pathognomonic green
birefringence of Congo red stained amyloid.
DNA quantification
Total DNA content within native tissue and acellular
matrices was measured using the DNeasy Blood and
tissue kit according to the manufacturer’s manual
(Qiagen, Hilden, Germany). Briefly, specimens were
digested with Proteinase K overnight, and DNA was
purified on a spin column; purity and yield of purified
DNA were assessed with spectrophotometric measure-
ments at 260 and 280 nm.
Scanning electron microscopy (SEM)
Samples were fixed in 2.5% v/v glutaraldehyde in 0.1 M
phosphate buffer and left for 24 h at 4 C. Following washing
with 0.1 M phosphate buffer, samples were cut into segments
of approximately 1 cm length and cryoprotected in 25%
sucrose, 10% glycerol in 0.05 M PBS (pH 7.4) for 2 h, then
fast frozen in nitrogen slush and fractured. Samples were then
placed back into the cryoprotectant at room temperature and
allowed to thaw. After washing in 0.1 M phosphate buffer (pH
7.4), the material was fixed in 1% OsO4/0.1 M phosphate
buffer (pH 7.3) at 3 C for 1.5 h and washed with 0.1 M
phosphate buffer (pH 7.4). After rinsing with water, speci-
mens were dehydrated in a graded ethanol-water series to
100% ethanol, critical-point dried using CO2 and finally
placed on aluminum stubs using sticky carbon taps. The
material was mounted to present fractured surfaces across the
parenchyma to the beam and coated with a thin layer of Au/Pd
(2 nm thick) using a Gatan ion beam coater. Images were




























recorded with a 7401 FEG scanning electron microscope (Jeol
Ltd, Welwyn Garden City, UK).
Protein composition of AA-mLdec and AA-mL
homogenates
Crude homogenates of livers from decellularized and
untreated amyloidotic AA transgenic mice [12] (AA-mLdec
or AA-mL, respectively) were prepared according to the AEF
extraction procedure from liver, as previously described [16].
Total protein content in homogenates was measured using
Pierce BCA protein assay kit (Thermo Scientific, Waltham,
MA) and 2 mg of total protein were analyzed using homo-
genous 15% PAGE under denaturing and reducing conditions
for further proteomics and immuno-enzymatic analyses. For
proteomic characterization, gel bands stained with colloidal
Coomassie Blue were trypsin digested before analysis of the
extracted peptide mixtures by MALDI-MS (AUTOFLEX III
Smartbeam Bruker, Billerica, MA). Peptide calibration mix-
ture (Bruker Daltonics, Billerica, MA) in the range between
1000 and 3500 Da was used as external standard.
Immunoblot analysis following 15% reducing SDS-PAGE
was performed with primary goat polyclonal anti-
mouse SAA1 antibody (0.2 mg/ml, R&D Systems,
Abingdon, UK) and secondary polyclonal anti-goat IgG
peroxidase conjugate (0.65 10-3 mg/ml, Dako, Glostrup,
Denmark).
Amyloid enhancing factor activity in AA-mLdec
Two groups of five wild-type female C57BL/6 mice
(Biological Services Unit, UCL) aged 12-15 weeks and
weighing 23–26 g received an injection of 0.2 ml of AA-mLdec
or AA-mL homogenates, followed by repeated subcutaneous
injections of 10% w/v casein in 0.01 M carbonate buffer.
Casein was given for 5 days per week from day 1 to 14. To
evaluate amyloid load, a single intravenous tracer dose of
125I-labeled serum amyloid P component (SAP) [17] was
administered on day 23. Whole body retention of 125I was
assessed after 24 and 48 h, and histological grading of Congo
red stained formalin-fixed, wax-embedded tissues was per-
formed as previously described [18,19].
Ethical approval
This study was ethically reviewed and approved by the UCL
Royal Free Campus Ethics and Welfare Committee and the
UK Home Office, and complied fully with European
Directive 86/609/EEC.
Results
Perfusion–decellularization of normal and amyloidotic
mouse livers
The decellularization protocol, based on antegrade perfusion
through the portal vein, was performed by sequential perfu-
sion of water, detergent and DNAse. Decellularization of
healthy and amyloidotic SAA transgenic mouse livers [12]
was completed within 46 h perfusion. During and following
decellularization, the whole liver gradually became increas-
ingly translucent with the dissolution of cells (Figure 1A).
Macroscopically, decellularized amyloidotic livers (AA-
mLdec) retained an opaque appearance after decellularization
(Figure 1A) when compared with the white translucent
appearance of decellularized healthy livers (H-mLdec; Figure
1A). With the exception of minor regions in some cases,
histological evaluation by H&E staining showed no evidence
of cell bodies or cellular material, including nuclei in
decellularized livers (Figure 1B). Spectrophotometric analysis
demonstrated the removal of DNA from the tissue, confirm-
ing the efficiency of the perfusion decellularization method
(Figure 1C). Nevertheless, the general liver tissue architecture
appeared fully preserved as shown by SR staining for
collagens (Figure 1D) and Van Gieson staining for elastin
(Figure 1E). Importantly, the presence of amyloid in the organ
did not affect the conduct or the efficacy of the perfusion and
the resulting organ scaffolds from amyloidotic livers had the
same hydrodynamic properties of pressure and flow rate as
the scaffolds from normal livers.
Amyloid is retained in the decellularized liver scaffold
Congo red staining for amyloid and immunohistochemical
staining with anti-SAA antibodies of sections of decellular-
ized amyloidotic liver were both strongly positive
(Figure 2A–C) in comparison with sections of non-decel-
lularized amyloidotic livers (Figure 2D–F) and decellularized
healthy organs (Figure 2G–I). Amyloid was clearly retained in
the decellularized scaffold and, in the example shown, the
amyloid was present throughout the scaffold, associated with
the stromal ECM, as well as with the portal tracts and central
veins.
Ultrastructural characterization of decellularized
mouse liver
Scanning electron microscopy was used to evaluate the 3D-
architecture and micro-structure of the ECM in both healthy
and amyloidotic tissue before (Figure 2J and K) and after
decellularization (Figure 2L and M). The overall extracellular
liver tissue micro-structure was apparently perfectly main-
tained after decellularization. The borders of the regions
corresponding to the hepatocyte–parenchyma were character-
ized by an organized fibrillar network in the decellularized
healthy liver (Figure 2L). In contrast, the decellularized
scaffold obtained from amyloidotic liver was markedly
thickened and overlaid with amyloid which appears as
granular spongy material occluding the fine porosity typical
of normal ECM. Decellularization strikingly highlighted
major differences between healthy and amyloidotic liver
(Figure 2L and M) that were not evident in the untreated
organs (Figure 2J and K).
SAA fragments are the main components in AA-mLdec
When equal amounts of protein from AA-mLdec and
AA-mL homogenates were run on a homogenous 15%
SDS-PAGE and stained with colloidal Coomassie blue, a
prominent doublet corresponding to AA amyloid protein
[20] was observed only in the decellularized sample
(Figure 3A). In situ trypsin digestion of the two main
bands and MALDI-MS analysis of the extracted peptides




























confirmed that they both contained the 1–70 amino-
terminal portion of murine SAA1 protein (Figure 3B).
Western blot analysis confirmed the presence of SAA1
fragments in the AA-mL homogenate together with some
full-length SAA protein (Figure 3C), the precursor of
AA.
Amyloid enhancing activity is preserved in AA-mLdec
It is known that tissue extracts from amyloidotic spleen/liver
contain ‘‘amyloid enhancing factor’’ (AEF) activity [16]. A
single injection of AA amyloid-containing tissue extracts
accelerates amyloid deposition resulting from subsequent
severe acute or prolonged inflammation, such as that evoked
by repeated casein injections [16,21]. When groups of five
mice received AA-mL or AA-mLdec, followed by casein
injections, they had similar amyloid load as shown by 125I-
labeled serum amyloid P component (125I-SAP) retention
(Figure 4A) and histochemical Congo red staining of both
spleen and liver (Figure 4B) [18,19].
Discussion
We report for the first time the decellularization of a
whole amyloidotic organ by intravascular perfusion with a
defined detergent-enzymatic technique. Importantly, the
Figure 1. Characterization of liver tissue scaffolds. (A) Macroscopic appearance before and after the decellularization procedure of native healthy (H-
mL), amyloidotic (AA-mL), decellularized healthy (H-mLdec) and amyloidotic (AA-mLdec). (B) Sections stained with H&E. (C) DNA quantification of
mouse livers to show reduction of DNA after decellularization confirming removal of cells. (D) Sections stained with SR. (E) Elastin Van Gieson
staining of mouse livers sections shows preservation of collagen and elastin after decellularization. Scale bar for 40 magnification: 50mm.




























decellularized liver preserves the amyloid deposits in the
ECM and allows a clear analysis of the intimate relationship
between ECM and amyloid. Indeed, cell removal highlighted
the structure of the ECM and high resolution 3D microscopic
analysis revealed that the constitutive tridimensional fibrillar
network of ECM was disrupted and overlaid with amyloid
leading to a marked modification of the very fine normal
structure of the ECM.
The SEM images suggest that such extensive and intimate
amyloid association with the ECM may have a profound effect
on crucial biomechanical properties of the ECM such as organ
elasticity and fluid permeability of the extracellular space.
These observations are in partial agreement with previous
studies in which SEM was used and results of
decellularization of portions of amyloidotic tissue, mostly
kidney, were reported [3,22]. These studies, while highlight-
ing the intimate relationship between ECM and amyloid,
report the presence of nodular aggregates with a granular
surface rather than the more uniform distribution of lumps of
amyloid along the tridimensional ECM structure shown in our
study. It is likely that this difference in amyloid distribution is
due to the different methods used to achieve tissue
decellularization. Decellularization obtained by flow perfu-
sion of the whole organ through the conserved natural
vascular tree may preserve the innate relationship between
amyloid and the 3D ECM meshwork. It is notable that
amyloid in the scaffold revealed by perfusion decellulariza-
tion retains the highly specific amyloid enhancing factor
Figure 2. Amyloid in decellularized amyloi-
dotic mouse liver. (A, B) Decellularized liver
scaffold from a heavily amyloidotic mouse
was stained by immunohistochemistry for
SAA and with Congo red, and viewed under
bright field illumination A and with crossed
polarizers B respectively. (C) No primary
antibody control for A. (D, E) Intact liver
from an SAA expressing amyloidotic mouse
stained for SAA and with Congo red and
viewed under bright field, D, and crossed
polarized light, E, showing amyloid in portal
tracts. In addition, nascent SAA within the
cytoplasm of hepatocytes gave strong immu-
nohistochemical signal. (F) No primary anti-
body control for intact liver. (G, H)
Decellularized healthy mouse liver did not
stain with SAA antibody or Congo red
viewed under bright field (G) or cross
polarized light (H). (I) no primary antibody
control for decellularized healthy mouse
liver. (J, K) SEM images of native normal
and amyloidotic livers respectively. (L, M)
SEM images of decellularized healthy and
amyloidotic liver, respectively. Scale bar
200mm, A–I; 2 mm, J–K, and 10 mm, L–M.




























property of homogenates of the whole amyloidotic organs.
This potent activity, attributable to amyloid fibrils themselves,
or fragments thereof [23] has a crucial influence on the
natural history of the disease once the first nuclei of amyloid
are formed with existing fibrils having the capacity to
catalytically accelerate the fibrillar conversion of protein
precursors. AEF [16,23] prepared from decellularized amy-
loidotic liver maintains this catalytic property thus
demonstrating that, with the conservation of amyloid fibril
primary structure, tinctorial and microscopic features, decel-
lularization did not affect the peculiar functional property of
priming amyloid growth and propagation.
In conclusion, here we have demonstrated that a 3D ECM
scaffold with a conserved vascular tree can be obtained from
amyloidotic mouse liver with retention of the natural structure
and specific amyloidogenic properties of the amyloid.
Ongoing studies will provide a proteomic characterization
of decellularized amyloidotic and non-amyloidotic liver. Once
this study is completed, decellularized amyloid organs will
represent an innovative experimental model to further inves-
tigate the disease and address crucial issues, such as, the
relationship between the ECM and amyloid fibrils and the
possible effects of natural fibrils on protein oligomerization as
well on organ recellularization. High-resolution 3D images of
amyloid in its natural environment may also be informative
about the recently discovered putative expansive forces
generated by fibril growth [24].
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